Top Markets
Coin of the day
PaxMedica, Inc. Common Stock PaxMedica, Inc. Common Stock

PaxMedica, Inc. Common Stock

PXMD
Rangering i aksjer #40912
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical... PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
Aksjekurs
$0.0005
Sist synkronisert: 2026-08-12
Markedsverdi
$63.13K
Endring (1 dag)
0.00%
Endring (1 år)
150.00%
Land
US
Handel PaxMedica, Inc. Common Stock (PXMD)

Kategori

P/S-forhold for PaxMedica, Inc. Common Stock (PXMD)
P/S-forhold per 2026 TTM: 0
Ifølge PaxMedica, Inc. Common Stock sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for PaxMedica, Inc. Common Stock fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE